Kymera completes STAT6 trial early; raises cash runway

Kymera Therapeutics reported enrollment for the KT-621 AD trial completed ahead of schedule and completed the quarter with $1.5 billion in cash, extending runway through 2029. The advancement is meaningful for the pipeline but has limited immediate impact on current market value.